A phase 1 trial of Amplimexon (Rm) (Imexon, Inj.) plus Taxotere (Rm) (docetaxel) in previously treated inoperable stage III and stage IV non-small cell lung cancer, locally advanced or metastatic previously treated breast cancer or hormone refractory prostate cancer

Trial Profile

A phase 1 trial of Amplimexon (Rm) (Imexon, Inj.) plus Taxotere (Rm) (docetaxel) in previously treated inoperable stage III and stage IV non-small cell lung cancer, locally advanced or metastatic previously treated breast cancer or hormone refractory prostate cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Imexon (Primary) ; Docetaxel
  • Indications Advanced breast cancer; Non-small cell lung cancer; Prostate cancer
  • Focus Adverse reactions
  • Sponsors AmpliMed
  • Most Recent Events

    • 13 Aug 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
    • 13 Aug 2008 The actual completion date for this trial is 1 Jul 2008 according to clinicaltrials.gov record.
    • 11 Aug 2008 Status changed from recruiting to in progress according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top